Please login to the form below

Not currently logged in


This page shows the latest Merck news and features for those working in and with pharma, biotech and healthcare.

FDA panel undermines Lilly and Incyte’s baricitinib hopes

FDA panel undermines Lilly and Incyte’s baricitinib hopes

targeting cancer immunotherapy epacadostat alongside Merck &Co/MSD’s Keytruda (pembrolizumab) in melanoma.

Latest news

More from news
Approximately 352 fully matching, plus 1,017 partially matching documents found.

Latest Intelligence

  • Implementing eHealth innovation Implementing eHealth innovation

    Innovation has driven Merck’s growth and performance to its 350-year celebration in 2018. ... is head of the global business franchise, general medicine and endocrinology at Merck KGaA.

  • The good, the bad and the ugly The good, the bad and the ugly

    Beyond Pfizer, the biggest positive movers in the top 20 include Shire, Bayer and Merck &Co. ... Merck &Co grew cardiovascular revenues by 130%, while GSK enjoyed a 214% uplift, mainly due to its PAH treatment Volibris.

  • The bulk of pharma digital spend fails to alter industry’s greenhorn status The bulk of pharma digital spend fails to alter industry’s greenhorn status

    Pfizer, AstraZeneca and Merck fare well on the Cx scores, largely due to the relevance of content provided to HCPs on the go, while Pfizer, Amgen and AZ outscored others on

  • Accelerating innovation Accelerating innovation

    That would be an ideal scenario, ”he said, but as to whether Ipsen has been talking to Merck &Co about its blockbuster immuno-oncology treatment Keytruda (pembrolizumab), he declined to comment.

  • Is AI changing the future of healthcare? Is AI changing the future of healthcare?

    Big pharma is investing in AI; there are now dedicated AI-based drug discovery firms that big players such as GSK, Merck, Sanofi and J&J are turning to, with significant

More from intelligence
Approximately 7 fully matching, plus 110 partially matching documents found.

Latest appointments

More from appointments
Approximately 37 fully matching, plus 132 partially matching documents found.

Latest from PMHub

  • Marketing strategy in complex environments

    Marketing strategy in complex environments. Age-old treatment protocols are being replaced with new and innovative treatment paradigms that will revolutionise the healthcare industry for years to come. Kulveer Singh and Mark Assenti talk through

  • Personalizing customer engagement in pharma

    Personalizing customer engagement in pharma. Barcelona eyeforpharma 2015 highlights: Philippe Kirby, Merck, David Hunt, Havas LYNX, and Richie Bavasso, Agnitio share their views on digital pharma trends. ... Summary/transcript. Barcelona eyeforpharma

  • Novartis CEO on patient value

    Including:. · How GSK, Pfizer and Merck are feeding patient voice, customer insight and point of value into their service strategies for user uplift. · ... You can see the full brochure which drills down in to each session here: . With attendees from

  • Sanofi on lack of customer understanding

    You'll hear how GSK, Pfizer and Merck are feeding Voice of Customer, Voice of Employee, Voice of Process and Point of Value in to their brand strategies for marketing uplift.

  • A stumble, but not a fall – what’s next for Opdivo?

    Their share price plunged by 17%, while competitor Merck &Co.'s surged by more than 10%. ... Rubbing salt into BMS’ s wounds, Merck's  Keytruda snagged a new FDA approval in head-and-neck cancer.

More from PMHub
Approximately 1 fully matching, plus 35 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Lucid Group Communications Limited

We are industry-leading thinkers when it comes to education. We use the latest academic thinking on the psychology of behaviour...

Latest intelligence

Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....